A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
We are a pioneering gene editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The promise of genomic medicines is supported by the advancing knowledge of the human genome and by harnessing the progress in technologies for cell therapy, gene therapy, and, most recently, gene editing. We believe this progress sets the stage for us to create medicines with the potential to have a durable benefit for patients. Our core capability in gene editing uses the technology known as CRISPR (clustered, regularly interspaced, short palindromic repeats) to allow us to create molecules that efficiently and specifically edit DNA. Our mission is to translate the promise of gene editing into a broad class of differentiated, transformational medicines for previously untreatable diseases. We have developed a proprietary gene editing platform based on CRISPR technology and we continue to expand its capabilities.
| Metric | TTM | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | 46M | - | 78M | - | - | 91M |
| Net Income | -200M | -237M | -153M | -220M | -193M | -116M |
| EPS | $-2.35 | $-2.88 | $-2.02 | $-3.21 | $-2.85 | $-1.98 |
| Free Cash Flow | -181M | -219M | -137M | -181M | -172M | -187M |
| ROIC | -77.9% | -58.1% | -43.9% | -61.1% | -34.8% | -29.5% |
| Gross Margin | - | - | - | - | - | - |
| Debt/Equity | 4.39 | 0.43 | 0.00 | 0.43 | 0.22 | 0.45 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -199M | -251M | -169M | -226M | -193M | -135M |
| Operating Margin | -428.7% | - | -216.6% | - | - | -148.6% |
| ROE | -1485.4% | -98.1% | -43.9% | -61.1% | -34.8% | -29.5% |
| Shares Outstanding | 98M | 82M | 76M | 69M | 68M | 59M |
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | |||
|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||
| Revenue | N/A | N/A | N/A | 91M | N/A | N/A | 78M | N/A | 46M |
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| SG&A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT | -120M | -114M | -141M | -135M | -193M | -226M | -169M | -251M | -199M |
| Op. Margin | N/A | N/A | N/A | -148.6% | N/A | N/A | -216.6% | N/A | -428.7% |
| Net Income | -120M | -110M | -134M | -116M | -193M | -220M | -153M | -237M | -200M |
| Net Margin | N/A | N/A | N/A | -127.8% | N/A | N/A | -196.1% | N/A | -430.8% |
| Non-Recurring | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 12M | 12M |
| Returns on Capital | |||||||||
| ROIC | -55.8% | -40.9% | -51.0% | -29.5% | -34.8% | -61.1% | -43.9% | -58.1% | -77.9% |
| ROE | -57.8% | -46.6% | -51.0% | -29.5% | -34.8% | -61.1% | -43.9% | -98.1% | -1485.4% |
| ROA | -32.2% | -26.2% | -26.3% | -20.3% | -28.4% | -42.9% | -30.7% | -56.4% | -99.1% |
| Cash Flow | |||||||||
| Op. Cash Flow | -9.4M | -46M | -41M | -180M | -164M | -177M | -132M | -210M | -180M |
| Free Cash Flow | -11M | -50M | -47M | -187M | -172M | -181M | -137M | -219M | -181M |
| Owner Earnings | -35M | -76M | -71M | -207M | -212M | -213M | -158M | -238M | -207M |
| CapEx | 2.1M | 4.8M | 6.2M | 7.2M | 8.0M | 4.1M | 4.7M | 8.8M | 0 |
| Maint. CapEx | 2.7M | 3.3M | 2.8M | 4.0M | 5.1M | 6.3M | 6.1M | 5.8M | 5.8M |
| Growth CapEx | 0 | 1.5M | 3.3M | 3.2M | 2.9M | 0 | 0 | 3.0M | 0 |
| D&A | 2.7M | 3.3M | 2.8M | 4.0M | 5.1M | 6.3M | 6.1M | 5.8M | 5.8M |
| CapEx/OCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Capital Allocation | |||||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Stock-Based Comp | 23M | 27M | 27M | 23M | 43M | 29M | 20M | 21M | 21M |
| Debt Repayment | 764K | 857K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Balance Sheet | |||||||||
| Net Debt | -322M | -337M | N/A | N/A | N/A | N/A | -323M | -212M | -107M |
| Cash & Equiv. | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 166M |
| Long-Term Debt | 7.5M | 32M | N/A | N/A | N/A | N/A | 0 | 52M | 52M |
| Debt/Equity | 0.04 | 0.14 | 0.94 | 0.45 | 0.22 | 0.43 | 0.00 | 0.43 | 4.39 |
| Interest Coverage | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Equity | 208M | 236M | 262M | 394M | 554M | 361M | 349M | 134M | 13M |
| Total Assets | 373M | 420M | 509M | 573M | 677M | 514M | 499M | 342M | 202M |
| Total Liabilities | 165M | 184M | 246M | 179M | 124M | 154M | 150M | 207M | 188M |
| Intangibles | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Retained Earnings | -306M | -416M | -549M | -665M | -858M | -1.1B | -1.2B | -1.5B | -1.5B |
| Working Capital | 295M | 339M | 404M | 361M | 460M | 297M | 278M | 212M | 212M |
| Current Assets | 332M | 375M | 464M | 419M | 507M | 357M | 341M | 289M | 289M |
| Current Liabilities | 37M | 36M | 60M | 58M | 47M | 60M | 63M | 77M | 77M |
| Per Share Data | |||||||||
| EPS | -2.98 | -2.33 | -2.68 | -1.98 | -2.85 | -3.21 | -2.02 | -2.88 | -2.35 |
| Owner EPS | -0.88 | -1.60 | -1.42 | -3.53 | -3.14 | -3.10 | -2.08 | -2.89 | -2.12 |
| Book Value | 5.15 | 5.00 | 5.26 | 6.72 | 8.20 | 5.25 | 4.60 | 1.63 | 0.14 |
| Cash Flow/Share | -0.23 | -0.97 | -0.81 | -3.07 | -2.43 | -2.58 | -1.74 | -2.55 | -1.99 |
| Dividends/Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.00 |
| Shares Out. | 40.4M | 47.2M | 49.9M | 58.6M | 67.5M | 68.7M | 75.9M | 82.3M | 97.6M |
| Valuation | |||||||||
| P/E Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -1.4 |
| P/FCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price/Book | 6.1 | 4.1 | 5.8 | 12.6 | 3.4 | 1.6 | 2.2 | 0.7 | 24.6 |
| Price/Sales | N/A | N/A | N/A | 19.9 | N/A | N/A | 8.5 | N/A | 7.1 |
| FCF Yield | -0.9% | -5.2% | -3.1% | -3.8% | -9.1% | -31.8% | -17.4% | -220.0% | -54.6% |
| Market Cap | 1.3B | 978M | 1.5B | 4.9B | 1.9B | 571M | 785M | 100M | 331M |
| Avg. Price | 20.65 | 32.66 | 24.02 | 30.80 | 46.39 | 14.88 | 8.73 | 5.23 | 3.39 |
| Year-End Price | 31.34 | 20.72 | 30.46 | 84.35 | 27.90 | 8.32 | 10.35 | 1.21 | 3.39 |
Editas Medicine, Inc. passes 0 of 9 quality checks, indicating weak fundamentals.
Editas Medicine, Inc. (EDIT) has a 5-year average return on invested capital (ROIC) of -45.5%. This is below average and may indicate limited pricing power.
Editas Medicine, Inc. (EDIT) has a market capitalization of $331M. It is classified as a small-cap stock.
Editas Medicine, Inc. (EDIT) does not currently pay a regular dividend.
Editas Medicine, Inc. (EDIT) operates in the Biological Products, (No Diagnostic Substances) industry, within the Healthcare sector.
Editas Medicine, Inc. (EDIT) generated $-219 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
Editas Medicine, Inc. (EDIT) has a debt-to-equity ratio of 0.43. This indicates a conservatively financed balance sheet.
Editas Medicine, Inc. (EDIT) reported earnings per share (EPS) of $-2.88 in its most recent fiscal year.
Editas Medicine, Inc. (EDIT) has a return on equity (ROE) of -98.1%. A negative ROE may indicate losses or negative equity.
The Ledger Terminal provides 8 years of financial data for Editas Medicine, Inc. (EDIT), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Editas Medicine, Inc. (EDIT) has a book value per share of $1.63, based on its most recent annual SEC filing.